← All diseases
Liver, kidneys and digestion
Fatty liver disease (MASH/NASH), advanced
Do you want to receive a message when there is new research about Liver Fat (MASH/NASH), advanced? This is possible with an account. Create a free account or log in.
Automatically tracked from PubMed and ClinicalTrials.gov, newest on top. Nothing ever disappears here: what you keep in your favorites remains findable. · RSS feed of this disease · only the strongest evidence
Read in plain language what each study is about? With Premium, a single sentence appears above each publication explaining what was studied — and you'll be notified as soon as new research on Liver Steatosis (MASH/NASH), Advanced is available. View what Premium costs.
Publications and studies (2550)
- Age, BMI, and Type 2 Diabetes Modify the Relationship Between PNPLA3 and Advanced Fibrosis in Children and Adults With NAFLD. (2024/05/01) ♡
- Screening for Fibrosis Promotes Lifestyle Changes: A Prospective Cohort Study in 4796 Individuals. (2024/05/01) ♡
- Efficacy of Yttrium-90 Transarterial Radioembolisation in Advanced Hepatocellular Carcinoma: An Experience With Hybrid Angio-Computed Tomography and Glass Microspheres. (2024/05/01) ♡
- Metabolic dysfunction-associated steatotic liver disease: Update and impact of new nomenclature on the American Association for the Study of Liver Diseases practice guidance on nonalcoholic fatty liver disease. (2024/05/01) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. New advances of adiponectin in regulating obesity and related metabolic syndromes. (2024/05/01) ♡
- [Mechanism of Biejiajian Pills against non-alcoholic steatohepatitis based on lipidomics]. (2024/05/01) ♡
- Preventive effects of caffeine on nicotine plus high-fat diet-induced hepatic steatosis and gain weight: a possible explanation for why obese smokers with high coffee consumption tend to be leaner. (2024/04/28) ♡
- [Effects of electroacupuncture of different intensities and durations on PERK/ATF4/CHOP signaling pathway in liver or non-alcoholic fatty liver disease rats]. (2024/04/25) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Bioactive Compounds Formulated in Phytosomes Administered as Complementary Therapy for Metabolic Disorders. (2024/04/09) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. MicroRNAs in adipose tissue fibrosis: Mechanisms and therapeutic potential. (2024/04/05) ♡
- Laboratory or animal researchiNo research in humans yet. Promising in a test tube or in mice unfortunately means nothing for patients. Integration of pharmacodynamics and metabolomics to reveal rhubarb anthraquinone protection against nonalcoholic fatty liver disease rat model. (2024/04/03) ♡
- Laboratory or animal researchiNo research in humans yet. Promising in a test tube or in mice unfortunately means nothing for patients. Huanglian-Hongqu herb pair improves nonalcoholic fatty liver disease via NF-κb/NLRP3 pathway in mice: network pharmacology, molecular docking and experimental validation. (2024/04/03) ♡
- Serum remnant cholesterol is a potential predictor of liver stiffness in patients with nonalcoholic fatty liver disease. (2024/04/01) ♡
- Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Prognostic factors in resolution of nonalcoholic fatty liver disease post bariatric surgery in adolescents. (2024/04/01) ♡
- Taohe Chengqi decoction alleviated metabolic-associated fatty liver disease by boosting branched chain amino acids catabolism in the skeletal muscles of type 2 diabetes mellitus. (2024/04/01) ♡
- Integrated spatial metabolomics and transcriptomics decipher the hepatoprotection mechanisms of wedelolactone and demethylwedelolactone on non-alcoholic fatty liver disease. (2024/04/01) ♡
- Commentary or editorialiAn expert's opinion or commentary, not new research. Metabolic Dysfunction-Associated Fatty Liver Disease: An Urgent Call for Global Action. (2024/04/01) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Mechanism insights into the pleiotropic effects of nobiletin as a potential therapeutic agent on non-alcoholic fatty liver disease (NAFLD). (2024/04/01) ♡
- Tangshen formula targets the gut microbiota to treat non-alcoholic fatty liver disease in HFD mice: A 16S rRNA and non-targeted metabolomics analyses. (2024/04/01) ♡
- Hedan tablet ameliorated non-alcoholic steatohepatitis by moderating NF-κB and lipid metabolism-related pathways via regulating hepatic metabolites. (2024/04/01) ♡
- Integrating transcriptomics and network pharmacology to reveal the mechanisms of total Rhizoma Coptidis alkaloids against nonalcoholic steatohepatitis. (2024/03/25) ♡
- Laboratory or animal researchiNo research in humans yet. Promising in a test tube or in mice unfortunately means nothing for patients. 6,7-Dimethoxycoumarin, Gardenoside and Rhein combination improves non-alcoholic fatty liver disease in rats. (2024/03/25) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Population-enriched innate immune variants may identify candidate gene targets at the intersection of cancer and cardio-metabolic disease. (2024/03/21) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Akkermansia muciniphila: a potential candidate for ameliorating metabolic diseases. (2024/03/20) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Extracellular vesicles targeting non-parenchymal cells: the therapeutic effect on liver fibrosis. (2024/03/19) ♡
- Multi-omics analysis of TLCD1 as a promising biomarker in pan-cancer. (2024/03/15) ♡
- Network pharmacological analysis on the mechanism of Linggui Zhugan decoction for nonalcoholic fatty liver disease. (2024/03/08) ♡
- Mitofusin-2 induced by exercise modifications lipid droplet mitochondria communication, promoting fatty acid oxidation in male mice with NAFLD. (2024/03/01) ♡
- Noninvasive tests to identify liver fibrosis in metabolic dysfunction-associated steatotic liver disease are affected by race. (2024/03/01) ♡
- Prevalence of steatotic liver disease, MASLD, MetALD and significant fibrosis in people with HIV in the United States. (2024/03/01) ♡
- Myosteatosis for Early Detection of Muscle Disorder in Patients With Liver Cirrhosis. (2024/03/01) ♡
- Alanine aminotransferase cutoffs for the pediatric fatty liver disease: Major impact of the reference population. (2024/03/01) ♡
- Evaluation of Hepatic Steatosis and Fibrosis Using Transient Elastography in Patients With Obstructive Sleep Apnea. (2024/03/01) ♡
- Meta-analysisiAll studies on one question combined and calculated together. This is the strongest form of research that exists: a single loose study can be coincidence, dozens together much less so. The label says something about the design, not about the outcome — which can also be that something does NOT work. Administration of silymarin in NAFLD/NASH: A systematic review and meta-analysis. (2024/03/01) ♡
- Laboratory or animal researchiNo research in humans yet. Promising in a test tube or in mice unfortunately means nothing for patients. Gypenoside XIII regulates lipid metabolism in HepG2 hepatocytes and ameliorates nonalcoholic steatohepatitis in mice. (2024/03/01) ♡
- Laboratory or animal researchiNo research in humans yet. Promising in a test tube or in mice unfortunately means nothing for patients. [Effect of Zuogui Jiangtang Qinggan Formula on lipid metabolism in db/db mouse model of type 2 diabetes mellitus complicated with non-alcoholic fatty liver disease] (2024/03/01) ♡
- Liver macrophage activation: Relation to hepatic histopathological changes in patients with metabolic associated steatotic liver disease. (2024/03/01) ♡
- Laboratory or animal researchiNo research in humans yet. Promising in a test tube or in mice unfortunately means nothing for patients. Hepatoprotective Effect of Lactiplantibacillus plantarum DSR330 in Mice with High Fat Diet-Induced Nonalcoholic Fatty Liver Disease (2024/02/28) ♡
- Alanine Aminotransferase (ALT) Test. (2024/02/27) ♡
- Systematic reviewiAll research on one question is searched according to fixed rules and compared side by side, so that no studies with poor outcomes are missed. The additive effect of herbal medicines on lifestyle modification in the treatment of non-alcoholic fatty liver disease: a systematic review and meta-analysis. (2024/02/23) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Silymarin: Unveiling its pharmacological spectrum and therapeutic potential in liver diseases-A comprehensive narrative review. (2024/02/16) ♡
- Isophorone-based AIegens fluorescent probe with red emission for targeting lipid droplets and identifying non-alcoholic fatty liver disease. (2024/02/05) ♡
- Meta-analysisiAll studies on one question combined and calculated together. This is the strongest form of research that exists: a single loose study can be coincidence, dozens together much less so. The label says something about the design, not about the outcome — which can also be that something does NOT work. Efficacy of traditional Chinese medicine combined with Silibinin on nonalcoholic fatty liver disease: A meta-analysis and systematic review. (2024/02/02) ♡
- Laboratory or animal researchiNo research in humans yet. Promising in a test tube or in mice unfortunately means nothing for patients. Seladelpar combined with complementary therapies improves fibrosis, inflammation, and liver injury in a mouse model of nonalcoholic steatohepatitis. (2024/02/01) ♡
- NLRP3 Deficiency in Nonimmune Cells Averts Obesity-Induced Fatty Liver Disease. (2024/02/01) ♡
- THE ROLE OF N6-METHYLADENOSINE METHYLTRANSFERASE RBM15 IN NONALCOHOLIC FATTY LIVER DISEASE. (2024/02/01) ♡
- Vascular endothelial cell-specific overexpression of CNP did not improve liver fibrosis in HFFCD-induced NASH, but did improve renal lesions. (2024/02/01) ♡
- Sestrin2 maintains hepatic immune homeostasis and redox balance partially via inhibiting RIPK3-mediated necroptosis in metabolic dysfunction-associated steatohepatitis. (2024/02/01) ♡
- Ginsenoside Rg5 inhibits lipid accumulation and hepatocyte apoptosis via the Notch1 signaling pathway in NASH mice. (2024/02/01) ♡
- Formononetin promotes fatty acid β-oxidation to treat non-alcoholic steatohepatitis through SIRT1/PGC-1α/PPARα pathway. (2024/02/01) ♡
codex.care does not provide medical advice. Always discuss symptoms, medication, and treatment choices with your own healthcare provider.